Susanna Naggie, MD

Associate Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail Dcri-2400 Pratt Street, Room 0311-BOX 3850, Durham, NC 27710
Phone (919) 684-2584
Email address susanna.naggie@duke.edu

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.

Education and Training

  • Fellow in Infectious Diseases, Medicine, Duke University, 2007 - 2009
  • Chief Medical Resident - VAMC, Medicine, Duke University, 2006 - 2007
  • Medical Resident, Medicine, Duke University, 2002 - 2005
  • M.D., Johns Hopkins University, 2002

Publications

Chan, A, Park, L, Collins, LF, Cooper, C, Saag, M, Dieterich, D, Sulkowski, M, and Naggie, S. "Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort." Open Forum Infectious Diseases 6, no. 1 (January 24, 2019): ofy273-null.

PMID
30697570
Full Text

Naggie, S. "Treating HCV Infection: It Doesn't Get Much Better Than This." Topics in Antiviral Medicine 26, no. 4 (January 2019): 104-108.

PMID
30641483
Scholars@Duke

AASLD-IDSA HCV Guidance Panel, . "Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 67, no. 10 (October 2018): 1477-1492.

PMID
30215672
Full Text

Proeschold-Bell, RJ, Evon, DM, Makarushka, C, Wong, JB, Datta, SK, Yao, J, Patkar, AA, Mannelli, P, Hodge, T, Naggie, S, Wilder, JM, Fried, MW, Niedzwiecki, D, and Muir, AJ. "The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial." Contemporary Clinical Trials 72 (September 2018): 73-85.

PMID
30006024
Full Text

MacBrayne, CE, Marks, KM, Fierer, DS, Naggie, S, Chung, RT, Hughes, MD, Kim, AY, Peters, MG, Brainard, DM, Seifert, SM, Castillo-Mancilla, JR, Bushman, LR, Anderson, PL, and Kiser, JJ. "Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate." The Journal of Antimicrobial Chemotherapy 73, no. 8 (August 2018): 2112-2119.

PMID
29746648
Full Text

Okeke, NL, Alenezi, F, Bloomfield, GS, Dunning, A, Clement, ME, Shah, SH, Naggie, S, and Velazquez, EJ. "Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort." Journal of Cardiac Failure 24, no. 8 (August 2018): 496-503.

PMID
29964194
Full Text

Naggie, S, Clement, M, Lusk, S, Osinusi, A, Himmel, T, Lucas, JE, Thompson, WJ, Dubois, L, Moseley, MA, Clark, PJ, Kottilil, S, and Patel, K. "Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations." Proteomics. Clinical Applications (July 30, 2018): e1800006-null.

PMID
30058111
Full Text

Naggie, S, Swiderska-Syn, M, Choi, S, Lusk, S, Lan, A, Ferrari, G, Syn, W-K, Guy, CD, and Diehl, AM. "Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection." Open Forum Infectious Diseases 5, no. 7 (July 2018): ofy138-null.

PMID
29992177
Full Text

Clement, ME, Collins, LF, Wilder, JM, Mugavero, M, Barker, T, and Naggie, S. "Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure." Infectious Disease Clinics of North America 32, no. 2 (June 2018): 407-423. (Review)

PMID
29778263
Full Text

Carlton-Smith, C, Holmes, JA, Naggie, S, Lidofsky, A, Lauer, GM, Kim, AY, Chung, RT, and of the ACTG A5327 study group, . "IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR." Journal of Viral Hepatitis 25, no. 5 (May 2018): 465-472.

PMID
29193564
Full Text

Pages